Persistent infection with Ebola virus under conditions of partial immunity

被引:64
作者
Gupta, M
Mahanty, S
Greer, P
Towner, JS
Shieh, WJ
Zaki, SR
Ahmed, R
Rollin, PE
机构
[1] Ctr Dis Control & Prevent, Special Pathogen Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Atlanta, GA USA
[3] Emory Univ, Sch Med, Vaccine Res Ctr, Atlanta, GA USA
[4] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA USA
关键词
D O I
10.1128/JVI.78.2.958-967.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Ebola hemorrhagic fever in humans is associated with high mortality; however, some infected hosts clear the virus and recover. The mechanisms by which this occurs and the correlates of protective immunity are not well defined. Using a mouse model, we determined the role of the immune system in clearance of and protection against Ebola virus. All CD8 T-cell-deficient mice succumbed to subcutaneous infection and had high viral antigen titers in tissues, whereas mice deficient in B cells or CD4 T cells cleared infection and survived, suggesting that CD8 T cells, independent of CD4 T cells and antibodies, are critical to protection against subcutaneous Ebola virus infection. B-cell-deficient mice that survived the primary subcutaneous infection (vaccinated mice) transiently depleted or not depleted of CD4 T cells also survived lethal intraperitoneal rechallenge for greater than or equal to25 days. However, all vaccinated B-cell-deficient mice depleted of CD8 T cells had high viral antigen titers in tissues following intraperitoneal rechallenge and died within 6 days, suggesting that memory CD8 T cells by themselves can protect mice from early death. Surprisingly, vaccinated B-cell-deficient mice, after initially clearing the infection, were found to have viral antigens in tissues later (day 120 to 150 post-intraperitoneal infection). Furthermore, following intraperitoneal rechallenge, vaccinated B-cell-deficient mice that were transiently depleted of CD4 T cells had high levels of viral antigen in tissues earlier (days 50 to 70) than vaccinated undepleted mice. This demonstrates that under certain immunodeficiency conditions, Ebola virus can persist and that loss of primed CD4 T cells accelerates the course of persistent infections. These data show that CD8 T cells play an important role in protection against acute disease, while both CD4 T cells and antibodies are required for long-term protection, and they provide evidence of persistent infection by Ebola virus suggesting that under certain conditions of immunodeficiency a host can harbor virus for prolonged periods, potentially acting as a reservoir.
引用
收藏
页码:958 / 967
页数:10
相关论文
共 42 条
[1]   The increasing burden of infectious diseases on hospital services at St. Mary's hospital Lacor, Gulu, Uganda [J].
Accorsi, S ;
Fabiani, M ;
Lukwiya, M ;
Onek, PA ;
Di Mattei, P ;
Declich, S .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 64 (3-4) :154-158
[2]   Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges-Courbot, MC ;
Capron, M ;
Lansoud-Soukate, J ;
Debré, P ;
Fisher-Hoch, SP ;
McCormick, JB ;
McCormick, JB ;
Georges, AJ .
NATURE MEDICINE, 1999, 5 (04) :423-426
[3]   The Ebola virus VP35 protein functions as a type IIFN antagonist [J].
Basler, CF ;
Wang, XY ;
Mühlberger, E ;
Volchkov, V ;
Paragas, J ;
Klenk, HD ;
Garcia-Sastre, A ;
Palese, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12289-12294
[4]   ENHANCED ESTABLISHMENT OF A VIRUS CARRIER STATE IN ADULT CD4+ T-CELL-DEFICIENT MICE [J].
BATTEGAY, M ;
MOSKOPHIDIS, D ;
RAHEMTULLA, A ;
HENGARTNER, H ;
MAK, TW ;
ZINKERNAGEL, RM .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4700-4704
[5]  
BELL SJD, 1992, CLIN EXP IMMUNOL, V90, P6
[6]   MECHANISMS OF MONOCLONAL ANTIBODY-MEDIATED PROTECTION AGAINST VIRULENT SEMLIKI FOREST VIRUS [J].
BOERE, WAM ;
BENAISSATROUW, BJ ;
HARMSEN, T ;
ERICH, T ;
KRAAIJEVELD, CA ;
SNIPPE, H .
JOURNAL OF VIROLOGY, 1985, 54 (02) :546-551
[7]   A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [J].
Bray, M ;
Davis, K ;
Geisbert, T ;
Schmaljohn, C ;
Huggins, J .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03) :651-661
[8]   The role of the Type I interferon response in the resistance of mice to filovirus infection [J].
Bray, M .
JOURNAL OF GENERAL VIROLOGY, 2001, 82 :1365-1373
[9]   Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995 [J].
Busico, KM ;
Marshall, KL ;
Ksiazek, TG ;
Roels, TH ;
Fleerackers, Y ;
Feldmann, H ;
Khan, AS ;
Peters, CJ .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S102-S107
[10]   Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients [J].
Bwaka, MA ;
Bonnet, MJ ;
Calain, P ;
Colebunders, R ;
De Roo, A ;
Guimard, Y ;
Katwiki, KR ;
Kibadi, K ;
Kipasa, MA ;
Kuvula, KJ ;
Mapanda, BB ;
Massamba, M ;
Mupapa, KD ;
Muyembe-Tamfum, JJ ;
Ndaberey, E ;
Peters, CJ ;
Rollin, PE ;
Van den Enden, E .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S1-S7